Comparison of the Effects of Crystalloid Cardioplegia and HTK Solution for Postoperative Troponin-I and CK-MB Levels After Pediatric Cardiac Surgery

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01548872
Recruitment Status : Unknown
Verified March 2012 by Selim Kuslu, Baskent University.
Recruitment status was:  Recruiting
First Posted : March 8, 2012
Last Update Posted : March 8, 2012
Information provided by (Responsible Party):
Selim Kuslu, Baskent University

Brief Summary:
The purpose of this study is to compare two different cardioplegia solutions effect on postoperative Troponin-I and CK-MB levels after pediatric cardiac surgery.

Condition or disease Intervention/treatment Phase
Myocardial Injury Drug: HTK solution Drug: crystalloid cardioplegia solution Phase 4

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 60 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Study Start Date : December 2011
Estimated Primary Completion Date : December 2012
Estimated Study Completion Date : December 2012

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Active Comparator: crystalloid cardioplegia solution
After aortic cross clamp 30ml/kg will be administered
Drug: crystalloid cardioplegia solution
30 ml/kg bolus in two minutes

Active Comparator: HTK solution
After aortic cross clamp 50ml/kg will be administered
Drug: HTK solution
50 ml/kg bolus in 2 minutes

Primary Outcome Measures :
  1. myocardial protective effect of HTK solution [ Time Frame: postoperative 48 hours ]
    to detect %33 difference in Troponin-I levels 4 hours postoperatively

Secondary Outcome Measures :
  1. hemodynamic and respiratory data [ Time Frame: postoperative 48 hours ]
    arterial pressures, heart rate,blood gas analysis

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   1 Month to 6 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients scheduled for elective pediatric cardiac surgery
  • Patients written informed consent for study participation

Exclusion Criteria:

  • redo surgery
  • allergy to study drugs
  • unstable blood pressure before cardiac surgery

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01548872

Contact: Selim Kuşlu +90 312 212 68 68 ext 1172
Contact: Pınar Zeyneloğlu + 90 312 212 68 68 ext 1800

Baskent University, Faculty of Medicine Recruiting
Ankara, Çankaya, Turkey, 06490
Principal Investigator: Selim Kuşlu         
Sponsors and Collaborators
Baskent University

Responsible Party: Selim Kuslu, Anesthesiology Resident, Baskent University Identifier: NCT01548872     History of Changes
Other Study ID Numbers: KA/11-152
First Posted: March 8, 2012    Key Record Dates
Last Update Posted: March 8, 2012
Last Verified: March 2012

Keywords provided by Selim Kuslu, Baskent University:
HTk solution
myocardial protection
pediatric cardiac surgery

Additional relevant MeSH terms:
Pharmaceutical Solutions
Cardioplegic Solutions
Diuretics, Osmotic
Natriuretic Agents
Physiological Effects of Drugs
Anesthetics, Local
Central Nervous System Depressants
Sensory System Agents
Peripheral Nervous System Agents